Bravo, PDL! A brief and succinct description of why investors might take an interest. No news. No patents, no license, no nothing apart from an effort to let the world know that they're moving and shaking........
Friday January 7, 6:43 pm Eastern Time
Company Press Release
SOURCE: Protein Design Labs
Protein Design Labs, Inc.
FREEMONT, Calif., Jan. 7 /PRNewswire/ -- Protein Design Labs (PDL) (Nasdaq: PDLI - news) is a leading developer of
humanized monoclonal antibodies. PDL's strategy is to leverage its technologies, expertise and intellectual property to become
a profitable, research-based pharmaceutical company that manufactures innovative products to meet important medical needs
and, in North America, markets its products and co-promotes those of certain of its partners.
PDL created the first humanized antibody to receive marketing approval, Zenapax® (daclizumab), which is marketed in the
U.S., Europe and other territories by PDL partner Hoffmann-La Roche Inc. and affiliates (Roche) for the prevention of acute
kidney transplant rejection. PDL receives royalties on Roche's sales in transplantation. PDL recently obtained certain
development and marketing rights from Roche to Zenapax for autoimmune indications and will share related net sales with
Roche.
Other PDL antibodies in clinical development include the SMART(TM) Anti-CD3 Antibody for transplantation and
autoimmune diseases, the SMART M195 Antibody for myeloid leukemias, the SMART 1D10 Antibody for B cell lymphoma,
the SMART Anti-L-Selectin Antibody for trauma and the SMART Anti-E/P-Selectin Antibody for stroke and autoimmune
diseases. Recently, PDL obtained from SmithKline Beecham Corporation certain rights to develop a humanized anti-IL-4
antibody for asthma.
PDL holds fundamental patents in the U.S., Europe and Japan for its antibody humanization technology and has signed license,
option or humanization agreements covering more than 30 antibodies, over half of which are in clinical development. In addition
to Zenapax, PDL receives royalty income under patent licenses from two antibodies: MedImmune's Synagis(TM) for
prevention of a serious viral infection in infants and Genentech's Herceptin® for breast cancer.
For more information, please visit the PDL website at www.pdl.com
SOURCE: Protein Design Labs
*******************************
Clearly states what they do. Clearly states their strategy. Throws in the word "innovative". This is what results from this sort of effort to communicate with shareholders.......
iqc.com
Would you like to know what GLIA told me when I asked about the preclinical data in narcoleptic dogs which was recently presented at the Neuroscience meetings? GLIA told me that nobody, except a few scientists like me, would be interested.
The current Board members are William A. Clarke, Theodore E.
Haigler, Jr., Ronald D. Henriksen, Irving S. Shapiro, John
L. Ufheil, Thomas O. Oesterling, Ph.D. and Robert P. Pinkas. |
